Octreotide has an important role in the medical management of acromegaly. Its place in the management of acromegaly as an adjuvant therapy after neurosurgery is well established with a well-demonstrated efficacy. It can also be used in certain clinical conditions as a neoadjuvant treatment. Clinicians and patients should be aware of the possible side effects of octreotide treatment.
The three classes of drugs available for treatment of acromegaly are SSAs, dopamine agonists and GH-receptor antagonists. SSAs were introduced in the 1980s, with octreotide being the first SSA to become available for clinical use.
Lanreotide was the second SSA introduced for clinical use and was developed in the 1990s. The first available pharmaceutical form of lanreotide was relatively short acting and required multiple daily dosing or subcutaneous infusion and this was soon superseded by the long-acting formulations of lanreotide. 12 A long-acting preparation of sustained release (SR) lanreotide extended the time interval of intramuscular injection to 7-14 days. 13, 14 There are several forms of octreotide available for medical therapies that are listed in Table 1 .
Other medical treatments are available in acromegaly and include dopamine agonists, such as bromocripitine or cabergoline. 18, 19 In the recent ACROSTUDY, which included 1,288 patients in real-life clinical practice, 88 % of patients received once per day pegvisomant alone, while 36 % were administered daily pegvisomant with another treatment. The results showed a biochemical control in 63 % patients after 5 years. 20 Two smaller studies showed a better biochemical response ranging from 84 % to 88 % in patients receiving a more optimal dose titration. 21, 22 Combination therapy including octreotide and one of the other of treatments seems to be a valuable therapeutic option in some cases. Several studies have evaluated the different combination options. Concerning the addition of dopamine agonists to SSAs a meta-analysis including 15 studies showed that adding dopamine in previously uncontrolled patients permit a normalisation of IGF-1 in 50 % patients. 23 Addition of pegvisomant in patients on octreotide therapy for those with uncontrolled acromegaly leads to a normalisation of IGF-1 in about 95 % of patients. Lanreotide ATG has a more favourable pharmacokinetic profile than SR lanreotide, which permits deep SC administration once every 28-56 days and by self-injection rather than muscular injection every 7-14 days. 31 Elimination of octreotide is principally via biliary excretion.
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Mechanisms of Action of SSAs
However the pharmacokinetic profile of octreotide is only slightly altered in patients presenting moderate to severe hepatic insufficiency, requiring no adjustment of its dosage. 32 Clinicians should be cautious in patients already taking cyclosporin because of a potential decreased resorption of this drug by octreotide. 33 Drugs that are metabolised by cytochrome P450 3A4, such as quinidine, have a reduction in their clearance in patients taking octreotide. Concerning octreotide itself, no drugs have been reported to alter its clearance.
Efficacy of SSAs
The efficacy of octreotide treatment as a primary treatment among different studies has shown that it achieves biochemical remission in a substantial number of patients. [34] [35] [36] The rate of biochemical response varies from 34 % to 60 %. The rate of significant tumour shrinkage (>20 %)
was estimated in about 75 % of patients included in a prospective study. 34 has shown that after four injections in half of the patients achieved biochemical remission. 41 A systematic review has showed a total of 33 % of patients experienced tumour shrinkage during lanreotide SR or ATG treatment in varying degrees from 10 to 77 %.
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A meta-analysis of 44 studies involving 1,852 patients compared the efficacy of lanreotide SR and octreotide LAR as postsurgical therapies.
The results showed that the biochemical efficacy of LAR octreotide is greater than that of lanreotide SR among patients unselected for prior SSA responsiveness. However, there are some limitations in the results of this meta-analysis because the biochemical criteria for acromegaly remission were heterogeneous among the studies. 43 When comparing the efficacy of LAR octreotide versus lanreotide ATG there was no significant difference in biochemical control or in tumour shrinkage. 44, 45 Lanreotide has the advantage of a prolonged injection interval in 50 % of patients. 
Side Effects of SSAs
SSA therapy is generally well tolerated in most patients and treatment discontinuation related to adverse effects (AEs) is mainly due to transient gastrointestinal symptoms [49] [50] [51] (see Table 2 ). The most frequent side effects of SSAs are diarrhoea, abdominal discomfort, nausea and flatulence in relation to the inhibition of pancreatic exocrine secretions. In rare cases, development of malabsorption and steatorrhoea can occur and the introduction of pancreatic enzymes can resolve the problem. By inhibiting cholecystokinin secretion, ocretotide causes the formation of a more lithogenic and viscous bile leading to gallbladder sludge and gallstones in up to 30 % to 60 % of the patients, respectively. 52 Ursodeoxycholic acid and chenodeoxycholic acid can be considered as a valid option to dissolve gallbladder sludge.
Erythema, injection-site discomfort and burning sensations are also frequently reported by patients under SSA treatment. These side effects can be avoided by warming the drug to room temperature before injection (storage of octreotide is required in a refrigerator).
The formation of painful subcutaneous nodules following repeated administration of lanreotide ATG has been described. 53 SSAs can also reduce gastrin secretion with a direct inhibitory effect on the secretion of intrinsic factor increasing the risk of chronic gastritis and pernicious anaemia. Surveillance should be carried out for pernicious anaemia and a B12 injection should be considered in such patients.
Concerning the potential effects on glucose homeostasis, octreotide influences remain difficult to predict. Indeed, octreotide may induce both inhibition of insulin secretion, but also improve insulin sensibility by inhibiting GH that itself cause insulin resistance.
A meta-analysis of 619 patients treated with octreotide showed no effects on glycated haemoglobin (HbA 1c ) or fasting glucose levels, but showed a worsening response to OGTT. 54 It could be considered Others side effects that must be explained to patients are hair loss and bradycardia. Diffuse alopoecia remains a rare complication of octreotide therapy that occurs less frequently with the slow-release preparation and is fully reversible after discontinuation.
Clinicians should also be aware of possible kidney injury induced by octreotide as a case of acute kidney failure caused by octreotide therapy for acromegaly has been reported. 55 Concerning pregnancy, data about octreotide use remain scarce as treatment was discontinued in most cases during pregnancy. There are, however, few studies showing that pregnancy is occasionally associated with a symptomatic increase of GH secretion during pregnancy. Medical treatment during pregnancy with dopamine agonists or SSAs appears to not cause significant complications or teratogenicity, but it may be associated with altered neonatal weight. Nevertheless, gestation may have a positive impact on acromegaly control both during and following pregnancy. [56] [57] [58] In the absence of consistent data about octreotide, clinicians should weigh out the potential risks against the possible benefits of octreotide treatment during pregnancy.
Finally, no tachyphylaxia has been reported during long-term therapy for patients taking octreotide for acromegaly; however, a tachyphylaxia was observed in a patient taking octreotide for a neuroendocrine gastrointestinal tumour.
Conclusion
SSAs are considered a mainstay in acromegaly therapy. Its efficacy is clearly demonstrated by numerous studies. However, clinicians and patients should be aware of the possible AEs, which can often be easily controlled and rarely require the discontinuation of treatment. n SSA = somatostatin analogue. 
